The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: Correlation with anti-HIV and virucidal activities

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 394-400

  Tummino, Peter J ^a   Harvey, Patricia J ^a   McQuade, Thomas ^a   Domagala, John ^a   Gogliotti, Rocco ^a   Sanchez, Joseph ^a   Song, Yuntao ^a   Hupe, Donald ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; CAPSID PROTEIN; DISULFIDE; VIRUS RNA; ZINC;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INACTIVATION; VIRUS NUCLEOCAPSID;

EID: 0031047399     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.394     Document Type: Article

References (29)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Aldovini, A., and R. A. Young. 1990. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J. Virol. 64:1920-1926.
3. Buckheit, R. W., M. G. Hollingshead, J. Germany-Decker, L. E. White, J. B. McMahon, L. B. Allen, L. J. Ross, W. D. Decker, L. Westbrook, W. Shannon, O. Weislow, J. P. Bader, and M. R. Boyd. 1993. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 21:247-255.
4. Cameron, B., M. Heath-Chiozzi, S. Kravcik, R. Mills, A. Potthoff, D. Henry, and J. Leonard. 1996. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir, abstr. LB6a. Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
5. D'Aquila, R. T., M. D. Hughes, V. A. Johnson, M. A. Fischl, J. P. Sommadossi, S. H. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, and M. S. T. I. Hirsch. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann. Intern. Med. 124:1019-1030.
6. Darlix, J. L., C. Gabus, M. T. Nugeyre, F. Clavel, and F. Barre-Sinoussi. 1990. Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus. J. Mol. Biol. 216:689-699.
7. Domagala, J. M., J. P. Bader, R. D. Gogliotti, J. P. Sanchez, M. A. Stier, Y. Song, J. V. N. Vara Prasad, P. J. Tummino, J. Scholten, P. Harvey, T. Holler, S. Gracheck, D. Hupe, W. G. Rice, and R. Schultz. A new class of anti-HIV agents targeted toward the nucleocapsid protein NCp7: the 2,2′-dithiobisbenzamides. Bioorg. Med. Chem., in press.
8. Domagala, J. M., R. D. Gogliotti, J. P. Sanchez, M. A. Stier, K. Musa, Y. Song, J. Loo, M. Reily, P. Tummino, P. Harvey, L. Sharmeen, D. Mack, J. Scholten, J. Saunders, and T. McQuade. 2,2′-Dithiobisbenzamides and 2-benzisothiazolones: two new classes of antiretroviral agents: SAR and mechanistic considerations. Drug Design Discovery, in press.
9. Dorfman, T., J. Luban, S. P. Goff, W. A. Haseltine, and H. G. Gottlinger. 1993. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein J. Virol. 67:6159-6169.
10. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
11. Fischer, R., and H. Hurni. 1964. On benzisothiazolones: a series with a wide range of bacteriostatic and fungistatic activity. Arzneim. Forsch. 14:1301-1306.
12. 11a. Gogliotti, R. Unpublished data.
13. Gorelick, R. J., S. M. Nigida, J. W. Bess, L. O. Arthur, L. E. Henderson, and A. Rein. 1990. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol. 64:3207-3211.
14. Green, L. M., and J. M. Berg. 1989. A retroviral Cys-Xaa2-Cys-Xaa4-His-Xaa4-Cys peptide hinds metal ions: spectroscopic studies and a proposed three-dimensional structure. Proc. Natl. Acad. Sci. USA 86:4047-4051.
15. Gulick, R., J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, R. Chiou, P. Deutsch, E. Emini, and J. Chodakewitz. 1996. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine, abstr. LB7. Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
16. Holler, T., S. K. Foltin, Q.-Z. Ye, and D. J. Hupe. 1993. HIV-1 integrase expressed in Escherichia coli from a synthetic gene. Gene 136:323-328.
17. Ji, X., G. J. Klarmann, and B. D. Preston. 1996. Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry 35:132-143.
18. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
19. Lange, J. M. 1996. Triple combinations: present and future. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 1):1077-9450.
20. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
21. Loo, J. A., T. P. Holler, J. Sanchez, R. Gogliotti, L. Maloney, and M. D. Reily. 1996. Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2′-dithiobis[benzamides] and benzisothazolones. J. Med. Chem. 39:4313-4320.
22. Nara, P. L., and P. J. Fischinger. 1988. Quantitative infectivity assay for HIV-1 and -2. Nature 332:469-470.
23. Okachi, R., H. Niino, K. Kitaura, K. Mineura, Y. Nakamizo, Y. Murayama, T. Ono, and A. Nakamizo. 1985. Synthesis and antibacterial activity of 2,2′-dithiobisbenzamide derivatives against mycobacterium species. J. Med. Chem. 28:1772-1779.
24. Peliska, J. A., S. Balasubramanian, D. P. Giedroc, and S. J. Benkovic. 1994. Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed DNA strand transfer reactions and modulates RNase H activity. Biochemistry 33:13817-13823.
25. Rice, W. G., J. G. Supko, L. Malpeis, R. W. J. Buckheit, D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. I. Sowder, L. O. Arthur, and L. E. Henderson. 1995. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270:1194-1197.
26. Rodriguez-Rodriguez, L., Z. Tsuschihashi, G. M. Fuentes, R. A. Bambara, and P. J. Fay. 1995. Influence of human immunodeficiency virus nucleocapsid protein on synthesis and strand transfer by reverse transcriptase in vitro. J. Biol. Chem. 270:15005-15011.
27. Sharmeen, L., T. McQuade, A. Heldsinger, R. Gogliotti, J. Domagala, and S. Gracheck. Mode of action of two novel benzamide disulfides (CI-1012 and C1-1013) with activity against HIV-1: inhibition of early phase of virus life cycle. Submitted for publication.
28. Summers, M. F., L. E. Henderson, M. R. Chance, J. W. J. Bess, T. L. South, P. R. Blake, I. Sagi, G. Perez-Alvarado, R. C. Sowder, D. R. Hare, and L. O. Arthur. 1992. Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1. Protein Sci. 1:563-574.
29. Tummino, P. J., J. D. Scholten, P. J. Harvey, T. P. Holler, L. Maloney, R. Gogliotti, J. Domagala, and D. Hupe. 1996. The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity. Proc. Natl. Acad. Sci. USA 93:969-973.